Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
PSA Shows Early Potential as an Independent Biochemical Marker for Breast Cancer Prognosis
September 1st 1995NEW YORK--The identification of prostate-specific antigen immunoreactivity (IR-PSA) in some cases of breast cancer has raised the possibility that PSA could be used as a biochemical marker for prognosis of breast cancer.
Commentary (Zujewski): Current Status of Endocrine Therapy for Metastatic Breast Cancer
September 1st 1995Endocrine therapy has been shown to be effective therapy for women with all stages of breast cancer, and the nonsteroidal antiestrogen tamoxifen is being evaluated as a potential preventive agent for this disease. Kimmick and Muss review the use of endocrine therapy for the treatment of patients with metastatic breast cancer. They discuss the basis for endocrine therapy and potential mechanisms of endocrine resistance, currently available and new agents, as well as new areas of investigation. I would like to highlight a few practical points regarding the use of endocrine therapy in the treatment of patients with metastatic breast cancer and some key areas of research.
Commentary (Lipton): Current Status of Endocrine Therapy for Metastatic Breast Cancer
September 1st 1995This year approximately 200,000 new cases of breast cancer will be diagnosed in the United States. Primary surgical treatment plus adjuvant therapy will cure two-thirds of these patients. The remainder, unfortunately, will experience disease recurrence at varying intervals after surgery.
Current Status of Endocrine Therapy for Metastatic Breast Cancer
September 1st 1995Hormonal manipulation is currently the mainstay of palliative care for metastatic breast cancer because it is well tolerated and produces significant responses in approximately one-third of unselected patients. Tamoxifen, a nonsteroidal antiestrogen, is currently considered first-line therapy. Second-line agents include progestins and aromatase inhibitors.
A Century of Breast Cancer Litigation Is 'Deconstructed'
August 1st 1995MIAMI BEACH, Fla--Breast cancer litigation is "a world whose activity is sometimes built upon old science, no science, or junk science," said Kenneth Kern, MD, of Hartford Hospital and the University of Connecticut School of Medicine, Farmington. In a presentation at the 12th Annual International Breast Cancer Conference, Dr. Kern offered the audience a "road map" for entry into that world.
Cost Studies Help Determine Best BMT Use
August 1st 1995HACKENSACK, NJ--The use of high-dose chemotherapy followed by bone marrow or stem cell transplantation (BMT) for metastatic breast cancer continues to be controversial, partially because of concerns that it is not cost effective, Christopher E. Desch, MD, said at a conference sponsored by the Northern New Jersey Cancer Center, Hackensack Medical Center.
New Studies Urged of Postmastectomy RT
August 1st 1995BALTIMORE--Irradiation of the chest wall following mastectomy has had an up and down history as breast cancer therapy. Now, says Allen S. Lichter, MD, director of Radiation Oncology, University of Michigan Medical Center, it is time to take another look at its value for patients with local or regional disease after surgery.
Implants May Hinder Chance for Early Detection of Breast Ca
August 1st 1995MIAMI BEACH, Fla--Between 1 and 2 million women in the United States have received silicone-gel-filled implants for breast augmentation, and, based on the general population risk, about 10% will ultimately develop breast cancer.
Survey Builds Case for Transplants in Breast Ca
August 1st 1995PARIS, France--Since 1991, breast cancer has been the most common diagnosis for which bone marrow transplants are performed. Therapy-related mortality has plunged to 6% or less, and the procedure's popularity has grown steadily to the point where more than a quarter of transplants for breast cancer are now done in women receiving adjuvant chemotherapy for stages II and III disease.
Commentary (Pritchard): Current Status of Vinorelbine For Breast Cancer
August 1st 1995Dr. Smith's excellent article summarizes the preclinical and clinical data obtained to date on the role of vinorelbine (Navelbine) in women with breast cancer. Introducing a new agent into the arena of breast cancer is fraught with logistic
Commentary (Fennelly): Current Status of Vinorelbine For Breast Cancer
August 1st 1995This is a timely, comprehensive overview of the current status of vinorelbine (Navelbine) in the treatment of metastatic breast cancer. For most patients with advanced breast cancer, there is no clear evidence that chemotherapy prolongs survival, although it can achieve clear improvements in quality of life [1].
ACS Helps Plan Mammography Screening Trial
August 1st 1995ATLANTA--The American Cancer Society's research program has awarded a $75,000 planning grant to the Union Internationale Contre le Cancer (UICC), based in Geneva, Switzerland, to study the feasibility of conducting a long-term international study on the effects of mammography in reducing breast cancer mortality in women in their 40s.
How One Company Decides When to Pay for Experimental Therapies
July 1st 1995Payment for bone marrow transplant (BMT) therapy for breast cancer from a managed care perspective will be influenced by clinical arguments put forth by research and clinical communities, outcomes measures over time, and the subscription
Responses to Anti-HER2 MoAb Seen
July 1st 1995ASCO LOS ANGELES--Two multi-institutional phase II studies of recombinant human anti-HER2/NEU antibody (rhuMAb HER2) in heavily pretreated stage IV breast cancer patients show some impressive responses, including some hepatic responses and a 25% response rate in patients given the antibody plus cisplatin (Platinol).
Molecular Markers Predict Clinical Outcome
July 1st 1995PARIS, France--University of Chicago researchers have discovered that the combination of a molecular marker of tumor virulence and a marker of metastatic potential can be used to reliably predict outcome in women with node-negative breast cancer, Ruth Heimann, MD, PhD, reported at the annual meeting of the American Radium Society.
National Breast Cancer Coalition Steps up Washington Lobbying
July 1st 1995WASHINGTON--The National Breast Cancer Coalition (NBCC) has announced its intention to lobby against congressional forces that want to reduce NIH funding. The coalition thus allies itself with professional societies that lobby Congress to increase federal funding for biomedical research.
Growth Factor Allows Effective Dose-Intensive Regimen in Advanced Breast Cancer Patients
July 1st 1995A dose-intensive outpatient regimen of doxorubicin and CMF (cyclophosphamide, methotrexate, and fluorouracil) with growth factor support proved to be effective and well tolerated in women with advanced breast cancer, Mark L. Graham,
Breast Preservation Seems Feasible in Chemohormonal Responders
July 1st 1995PARIS, France--Radiation therapy is a reasonable alternative to mastectomy in women with stage IIIA and IIIB breast cancer who respond to aggressive chemohormonal therapy, a prospective trial conducted at the University of Michigan has found.
MRI May Reduce the Number of Biopsies for Breast Cancer
June 1st 1995Like a colorblind coach who can see all the players but cannot tell who is friendly, x-ray mammography is effective in finding suspicious breast lesions but is not reliable in determining which ones are cancerous. Because of this uncertainty, about
Counseling Must Go Hand in Hand With Genetic Testing for Breast Cancer
June 1st 1995NEW YORK--What should have been good news for a woman whose family had a history of breast cancer--that she did not carry the breast cancer gene (BRCA1)--proved bittersweet, since the woman had had bilateral prophylactic mastectomies 5 years earlier.
Aggressive 16-Week Multidrug Regimen Improves Breast Cancer Survival
June 1st 1995LOS ANGELES--An aggressive 16-week, multidrug chemotherapy regimen afforded a survival advantage over six cycles of CAF (cyclophosphamide, Adriamycin, and fluorouracil) in 646 women with receptor-negative, node-positive breast cancer, preliminary results of an Intergroup study have shown.